Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Tue, 30.07.2024
Formycon AG
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab)
The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries [ … ]
Thu, 13.06.2024
Formycon AG
Press Release // June 13, 2024
Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
First patient entered Phase I clinical trial “Dahlia” to compare the pharmacokinetics (PK), safety and tolerability of FYB206 with the reference product Keytruda®[i] (First Patient In).
"Dah [ … ]
Wed, 08.05.2024
Formycon AG
Press Release // May 8, 2024
Formycon reports on successful operating business and financial figures for the first quarter of 2024
Group revenue amounts to € 17.7 million and corresponds to plan
Group EBITDA of € -5.5 million reflects investments in pipeline and corporate development
Adjusted Group EBITDA of € -1.2 million shows strong at-equi [ … ]
Tue, 07.05.2024
Formycon AG
Press release // 07 May 2024
Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
Formycon proposes to the Annual General Meeting a more international focus and expansion of the Supervisory Board to five members
With Colin Bond, Dr. Bodo Coldewey and Nicholas Haggar, three new candidates with relevant industry and financial [ … ]
Thu, 02.05.2024
Formycon AG
Press Release // May 02, 2024
Formycon hosts conference call on the results of the first quarter 2024
Planegg-Martinsried – Formycon AG (FWB: FYB, 'Formycon') today announced details of the conference call to release the results of the first quarter 2024 on May 08, 2024. The management board will discuss the company's developments and key financi [ … ]
Thu, 25.04.2024
Formycon AG
Press release // April 25, 2024
Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
Preliminary results 2023 confirmed
Group revenue increases by 83% compared to the previous year to a total of € 77.7 million
Positive Group EBITDA of around € 1.5 million and adj [ … ]
Fri, 12.04.2024
Formycon AG
Press release // 12 April 2024
Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
Group revenue increase by 83% compared to the previous year to a total of € 77.7 million
Positive Group EBITDA of around € 1.5 million achieved
New key financial performance indicator (KPI) " [ … ]
Thu, 11.04.2024
Formycon AG
Press release // April 11, 2024
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
Lucentis® biosimilar FYB201 is an effective and cost-effi [ … ]
Mon, 18.03.2024
Formycon AG
Press release // March 18, 2024
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Munich, Germany – Formycon AG (FSE: FYB) and its commercialization partner Fresenius Kabi today announced the signing of a settlement agreement with Johnson & Johnson concerning the comme [ … ]
Mon, 11.03.2024
Formycon AG
Press release // March 11, 2024
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Commercialization partner MS Pharma wins government tender for Ranibizumab in Saudi Arabia
Commercial launch of FYB201/Ravegza® planned for second quarter of 2024
Further launches planned throughout 2024 to improve access [ … ]